Strikingly, this triple combination comprising Eht1864, venetoclax and midostaurin synergistically reduced the viability of FLT3-ITD midostaurin-resistant cells and cells obtained from patients with FLT3-ITD refractory AML by reducing MCL1 and BCL-2 expression. The gene discussed is BCL2; the disease is acute myeloid leukemia.